GET DAILY SIGNALSDXCM vs LIVN: Weighing the +25% YTD Medtech Leader Against Its Competitor
Key Takeaways
- Tickeron AI Verdict: Based on observable trend consistency, margin expansion, and catalyst breadth, Tickeron's AI currently favors DXCM in this head-to-head comparison.
- DXCM (DexCom) is a large-cap continuous glucose monitoring (CGM) leader delivering beat-and-raise results with expanding margins.
- LIVN (LivaNova) is a mid-cap medical device maker trading near 52-week highs, driven by cardiopulmonary and neuromodulation growth.
- Both stocks carry favorable analyst ratings, but DXCM offers greater scale, a larger addressable market, and multiple clinical and reimbursement catalysts.
- Explore DXCM Major News and DXCM Today's Price Move, as well as LIVN Major News and LIVN Today's Price Move, for up-to-the-minute developments on each ticker.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Setting the Context for This Comparison
Investors evaluating medical device and technology names often weigh large, established franchises against smaller, faster-moving challengers. This stock comparison examines DXCM, a global leader in continuous glucose monitoring, and LIVN, a diversified maker of cardiopulmonary and neuromodulation devices. Both companies serve unmet clinical needs, operate in defensive healthcare markets, and have posted improving relative performance in recent quarters. The comparison is most relevant to growth-oriented traders and investors assessing relative performance, market positioning, and momentum between two profitable, innovation-driven medtech businesses with very different market capitalizations and growth drivers. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
DXCM Overview and Recent Performance
DXCM is DexCom, Inc., a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes and metabolic health. Recent market activity has been constructive, with the stock gaining roughly 25% year-to-date and outperforming its broader industry. In its most recent quarter, DexCom reported revenue of $1.34 billion, up about 11% year over year, alongside adjusted earnings per share (EPS) that beat consensus estimates. U.S. revenue growth accelerated to roughly 14%, while international growth moderated to about 5% due to tougher reimbursement comparisons.
Sentiment has been supported by expanding margins—gross margin approached 65% and operating margin exceeded 25%—as well as the rollout of the G7 15 Day sensor, which management expects to reach nearly half of its U.S. customer base by year-end. A key catalyst is the CONNECT study, published in the New England Journal of Medicine, which showed meaningful A1C (a measure of average blood sugar) improvement in non-insulin Type 2 diabetes patients. Management also raised full-year revenue guidance and authorized an additional $1 billion share repurchase program. From what I see, the margin trajectory here stands out as particularly durable.
LIVN Overview and Recent Performance
LIVN is LivaNova PLC, a medical technology company operating in two segments: Cardiopulmonary (heart-lung machines, oxygenators, and related equipment) and Neuromodulation (the VNS Therapy system for drug-resistant epilepsy and depression). The stock has been a strong performer, with its market capitalization rising sharply year over year and shares trading near 52-week highs. In its latest quarterly report, LivaNova posted revenue of about $393 million, up roughly 10% year over year, and raised its full-year adjusted EPS outlook.
Performance has been driven by double-digit growth in the Cardiopulmonary and epilepsy businesses, aided by a roughly 50% increase in U.S. Medicare reimbursement for VNS Therapy effective in 2026. Investor attention has also centered on the company's emerging obstructive sleep apnea (OSA) opportunity, anchored by its PolySync programming technology and the aura6000 system. Several analysts raised price targets following the recent report, reflecting an improved growth and margin trajectory. I’m watching this closely for any shifts in procedure volume trends.
Side-by-Side Analysis
The two companies differ sharply in scale and focus. DXCM is a roughly $30 billion-market-cap pure play in diabetes technology, while LIVN is a roughly $5 billion-market-cap diversified device maker spanning cardiopulmonary and neuromodulation. DXCM's growth thesis centers on expanding CGM adoption beyond insulin-dependent patients, supported by clinical data and reimbursement tailwinds. LIVN's thesis leans on durable consumables demand, improved VNS reimbursement, and a longer-dated OSA pipeline.
On momentum, both have performed well, but DXCM offers greater consistency through manufacturing efficiencies and margin expansion, while LIVN carries higher cyclical sensitivity to procedure volumes and reimbursement timing. In valuation terms, LIVN trades at a lower forward earnings multiple, while DXCM commands a premium for its larger addressable market and growth runway. Risk factors include intense CGM competition for DXCM and clinical or regulatory execution for LIVN.
Tickeron AI Verdict
Weighing trend consistency, financial momentum, catalyst breadth, and market positioning, Tickeron's AI currently leans toward DXCM as the more favorable setup of the two. The case rests on DexCom's larger scale, accelerating U.S. growth, expanding margins, and a pipeline of near-term catalysts—including the CONNECT study's implications for broader Type 2 coverage and the ongoing G7 15 Day rollout. That said, LIVN presents a compelling, higher-momentum alternative with improving reimbursement economics. The AI verdict is probabilistic rather than definitive, reflecting a relative preference for DXCM based on currently observable data.
Integrating AI Tools Into My Workflow
When comparing names like these, I often turn to Tickeron’s AI Trading Bots to simulate different strategies and see how they perform under current conditions. These bots offer a range of approaches tailored to various market environments, providing an additional layer of data-driven perspective beyond traditional fundamentals and helping refine relative positioning between stocks such as DXCM and LIVN.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for DXCM turns positive, indicating new upward trend
DXCM saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 62 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Oscillator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 31 of 45 cases over the following month. The odds of a continued upward trend are 69%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 62 cases where DXCM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement